Clinical trial
Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph…
NCT00243594 · Radboud University Medical Center, Other · Completed
Key facts
| NCT number | NCT00243594 |
|---|---|
| Title | Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection |
| Official title | Active Immunization of Patients With Stage III and IV Melanoma in Whom a Regional Lymph Node Dissection is Planned, With Peptide-Pulsed Dendritic Cells: Evaluation of in Vivo Immune and Clinical Response and Migration |
| Lead sponsor | Radboud University Medical Center, Other |
| Collaborators | Dutch Cancer Society |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma Stage III or IV |
| Intervention type | Biological |
| Interventions | Peptide-pulsed dendritic cells |
| Enrollment | 40 |
| Start date | Sep 1, 1999 |
| Primary completion | Jan 1, 2009 |
| First posted | Oct 24, 2005 |
| Last update posted | Feb 19, 2009 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: